BCL2 and diffuse large B-cell lymphoma: Our data together suggest that the combinations of MYC, BCL2 and BCL6 protein expression assessed by IHC are reliable prognostic predictors and could be used in the future as prognostic markers for stratification of patients with DLBCL for novel therapies.